TOP TEN perturbations for 39891_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39891_at
Selected probe(set): 39891_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39891_at (39891_at) across 6674 perturbations tested by GENEVESTIGATOR:

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):2.4670067
Number of Samples:4 / 8
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):2.4264927
Number of Samples:7 / 8
Experimental dendritic cell study 6 (gardiquimod)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):2.096075
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):2.029706
Number of Samples:2 / 4
Experimental glioma study 17 (glioblastoma; unsorted)
Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)

Relative Expression (log2-ratio):1.9806252
Number of Samples:4 / 4
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (CpG A; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO lung cancer study 1 (neuroendocrine carcinoma; primary)

Relative Expression (log2-ratio):1.9379034
Number of Samples:2 / 6
Experimental expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS).
Control expO lung cancer study 1 (neuroendocrine carcinoma; primary)
Primary tumor tissue samples obtained from the lung of patients with neuroendocrine carcinoma.

expO lung cancer study 1 (squamous cell carcinoma, NOS; primary) / expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-1.9265528
Number of Samples:40 / 2
Experimental expO lung cancer study 1 (squamous cell carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the lung of patients with squamous cell carcinoma (NOS).
Control expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS).

expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO lung cancer study 1 (large cell carcinoma, NOS; primary)

Relative Expression (log2-ratio):1.9235601
Number of Samples:2 / 9
Experimental expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS).
Control expO lung cancer study 1 (large cell carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the lung of patients with large cell carcinoma (NOS).

glioma study 17 (astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):1.7960701
Number of Samples:3 / 3
Experimental glioma study 17 (astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from low grade astrocytoma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 36 ± 7 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO lung cancer study 1 (bronchiolo-alveolar adenocarcinoma; primary)

Relative Expression (log2-ratio):1.7737255
Number of Samples:2 / 13
Experimental expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS).
Control expO lung cancer study 1 (bronchiolo-alveolar adenocarcinoma; primary)
Primary tumor tissue samples obtained from the lung of patients with bronchiolo-alveolar adenocarcinoma.